Search
rhThrombin
go.drugbank.com/drugs/DB04923ApprovedWithdrawnThrombin is used in more than 1 million surgeries each year in the United States. Currently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. … ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery.
Sodium lauryl sulfoacetate
go.drugbank.com/drugs/DB13157ApprovedWithdrawnSodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
Synonyms: Lathanol LALIsosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalIsosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the prevention of angina.
Potassium cation
go.drugbank.com/drugs/DB01345ApprovedThe cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.
Dicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexMercaptopurine
go.drugbank.com/drugs/DB01033ApprovedInvestigationalIt interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. … An antimetabolite antineoplastic agent with immunosuppressant properties.
Categories: OAT3/SLC22A8 Substrates with a Narrow Therapeutic IndexBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalIn this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. … Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE).
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCalcium alginate
go.drugbank.com/drugs/DB13372ApprovedWithdrawnCategories: Compounds used in a research, industrial, or household settingGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.